Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Dividends Paid - Common (2020 - 2024)

Maravai Lifesciences Holdings (MRVI) has 5 years of Dividends Paid - Common data on record, last reported at -$78000.0 in Q4 2024.

  • For Q4 2024, Dividends Paid - Common changed N/A year-over-year to -$78000.0; the TTM value through Sep 2025 reached $494000.0, down 13.64%, while the annual FY2024 figure was $494000.0, 94.86% down from the prior year.
  • Dividends Paid - Common reached -$78000.0 in Q4 2024 per MRVI's latest filing, down from $572000.0 in the prior quarter.
  • Across five years, Dividends Paid - Common topped out at $96.7 million in Q4 2020 and bottomed at -$78000.0 in Q4 2024.
  • Average Dividends Paid - Common over 5 years is $27.4 million, with a median of $30.9 million recorded in 2022.
  • Peak YoY movement for Dividends Paid - Common: skyrocketed 40961.48% in 2021, then plummeted 96.94% in 2023.
  • A 5-year view of Dividends Paid - Common shows it stood at $96.7 million in 2020, then crashed by 51.26% to $47.2 million in 2021, then crashed by 34.43% to $30.9 million in 2022, then tumbled by 95.78% to $1.3 million in 2023, then tumbled by 105.98% to -$78000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Dividends Paid - Common were -$78000.0 in Q4 2024, $572000.0 in Q2 2024, and $1.3 million in Q2 2023.